The European Patent Office has granted a further European patent to the company, entitled “Antigen and method for production thereof”.

The granted European patent follows the approval of the US-member of this patent family already in 2018 under US Patent 10,159,729 B2.

“We’re excited about this important milestone that provides additional protection for our core technologies. The market for therapeutic antibodies, vaccines and biologics is ever expanding. Securing these patents protects our innovative platform and further strengthens our position by supplementing our foundational and follow-up patents that have already been granted to Salipro Biotech in many countries, including US, EU, China and Japan,” says Jens Frauenfeld, CEO, Salipro Biotech.

Therapeutics against drug targets such as GPCRs, ion channels and transporters

The patents cover the composition-of-matter, methods and uses of the company’s novel antigen technology, strengthening Salipro Biotech’s platform technologies for the discovery and development of next generation therapeutics against challenging drug targets such as GPCRs, ion channels and transporters, states the company.

“We’re constantly increasing our collaborations, partnerships and licensing agreements with major pharma companies on a wide range of challenging drug targets. Expanding our already strong patent portfolio further will enable us to increase the value of such collaborations for our partners as well as moving towards building our own discovery pipeline,” says Maria Knudsen, Business Development Director at Salipro Biotech.

Photo of Jens Frauenfeld, CEO, Salipro Biotech